Ann: CEO's address to AGM , page-4

st this next paragraph , explaining the Oral NNZ2566 Trials which should be completed in 18 Months time, if successful will create value far in Excess of todays market cap.

Again fully funded and easy trials easy recruitment and low efficacy barrier.

" planning to start a Phase II trial in Q4 this year, in time for high school and college football and soccer
seasons in the US. The study will be led by the University of Pittsburgh Sports Medicine Concussion
Program, one of the leading centers for research in concussion. The direct costs of the trial will be
funded by the US Army which has committed approximately US$3.8m for the study and for
development of NNZ-2566 oral. Patients enrolled in the trial will be athletes who are already enrolled
in a screening program called Immediate Post-Concussion Assessment and Cognitive Testing or
ImPACT®. People enrolled in ImPACT® have baseline, pre-injury neurocognitive assessments
completed such that each subject will essentially serve as his or her own control. This design
increases the statistical power and decreases sample size requirements, allowing us to use return to
baseline as the measure of efficacy which is much more sensitive than comparison with normative,
general population-based data.
Potential subjects will be identified by personnel trained by the UPMC group at the sports field rather
than waiting for them to show up at the emergency department. All patients will have an MRI with
Diffusion Tensor Imaging or DTI to help identify patients with specific types of brain injury which will
be part of the analysis at the end of the study. DTI is particularly useful for imaging injuries in the
axons that make up the white matter of the brain. So-called diffuse axonal injury or axonal shearing
often occurs as a consequence of acceleration – deceleration injuries which are common among
athletes and blast-injured soldiers. We are forecasting that enrollment in the Phase II trial will be
completed within a year."